- Home
- AOD vs ARVN Comparison
AOD vs ARVN Comparison
Compare AOD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AOD | ARVN |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 970.0M | 806.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | AOD | ARVN |
|---|---|---|
| Price | $9.71 | $12.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $17.80 |
| AVG Volume (30 Days) | 423.5K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 12.95% | N/A |
| EPS Growth | ★ 213.63 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | $72,962,082.00 | ★ $312,300,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.44 | ★ N/A |
| Revenue Growth | N/A | ★ 93.86 |
| 52 Week Low | $6.99 | $5.90 |
| 52 Week High | $9.14 | $22.48 |
Technical Indicators
Market Signals| Indicator | AOD | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 55.73 |
| Support Level | $9.66 | $12.47 |
| Resistance Level | $9.74 | $13.56 |
| Average True Range (ATR) | 0.08 | 0.56 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 84.21 | 40.00 |
Price Performance
Historical ComparisonAbout AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.